SOURCE Padagis

Michigan stretches funding to enhance its naloxone distribution program, expand access and potential to save more lives by adding cost effective generic naloxone to its state contract

ALLEGAN, Mich., July 8, 2025 /PRNewswire/ -- Padagis®, a Michigan-based leader in generic pharmaceuticals, announced today that the State of Michigan has added its over-the-counter (OTC) Naloxone HCl Nasal Spray 4 mg to the state's distribution network. This partnership will help expand access to life-saving medication and maximize the impact of federal overdose prevention funding in the state.

"Michigan distributed more than 419,000 naloxone kits last fiscal year and now that they are supplementing with our generic version this year the state can stretch its funding further and reach even more people," said Pamela Hoffman, President of Padagis. "Increasing access to naloxone is a key factor for states aiming to reduce opioid overdose deaths. We're proud to be able to provide our home state of Michigan with high-quality, life-saving medication at a significantly lower cost."

Padagis will distribute its naloxone spray to more than 1,000 sites across Michigan through its dedicated portal, which also offers training materials on recognizing opioid overdoses and education on proper nasal spray administration.

"At Padagis, we're committed to reducing healthcare costs and improving access to essential medications. Our partnership with the State of Michigan reflects that mission," continued Hoffman. "Since launching our OTC naloxone in 2023, we've focused on lowering barriers to this critical medication, and we're proud to make it more accessible and affordable right here in our home state. Michigan is setting a powerful example of how to maximize federal and state resources to protect public health and serve its communities."

To learn more about Padagis and its OTC naloxone nasal spray, visit padagisnaloxone.com.

About Padagis
Based in Allegan, Michigan, Padagis is relentlessly committed to reducing healthcare costs and improving accessibility by delivering high-quality medicine through innovative approaches. The pharmaceutical company is a leading provider of extended topical medications and other specialty drugs primarily in the United States.  One of Padagis' flagship products is Naloxone, an over-the-counter nasal spray that acts as an antidote for opioid overdoses. Padagis is committed to making its Naloxone nasal spray widely available to help put an end to the opioid crisis and save lives. Padagis employs over 1,300 people worldwide. Visit Padagis online at http://www.padagis.com.

Media Contact: [email protected], 303.877.0738

©PR Newswire. All Rights Reserved.

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]